# Thermo Fisher Scientific (TMO) Financial Model Free Excel 3-statement financial model and company analysis for Thermo Fisher Scientific. - Canonical: https://finamodel.com/companies/thermo-fisher-scientific - Industry: Laboratory Equipment - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/TMO.xlsx ## Model Purpose This model provides a comprehensive equity valuation and capital allocation forecast for Thermo Fisher Scientific, enabling an equity research analyst to determine the company's intrinsic value and assess its capacity for future transformational M&A. ## Company Overview Thermo Fisher Scientific is the world's largest supplier of scientific instrumentation, reagents, consumables, and software to life sciences, clinical, and industrial laboratories. The company also provides extensive outsourced clinical trial and contract manufacturing services to the pharmaceutical industry. Business segments (approximate gross revenue contribution before eliminations): * Laboratory Products and Biopharma Services (52%) * Life Sciences Solutions (23%) * Analytical Instruments (19%) * Specialty Diagnostics (10%) Key geographies include North America (approx. 50%), Europe (approx. 25%), and Asia-Pacific including China (approx. 20%). The business model is a hybrid of recurring consumables and services (asset-light, high visibility) and capital equipment sales (asset-heavy, cyclical). Thermo Fisher holds a dominant competitive position, often ranking first or second in its core markets, competing against Danaher, Agilent, and IQVIA. Recent major events include the 2021 acquisition of PPD for $17.4 billion (significantly expanding the clinical research business) and the 2024 acquisition of Olink Holding AB to bolster its proteomics portfolio. ## Revenue Deep Dive ### Life Sciences Solutions * **Segment name:** Life Sciences Solutions * **Revenue driver formula:** (Biopharma R&D Spend x TMO Market Share) + (Academic Funding x TMO Win Rate) * **Historical growth rate:** Highly volatile recently due to COVID-19 roll-off; normalised long-term CAGR is 5-7%. * **Key growth levers and headwinds:** Driven by biological research activity, mRNA technology adoption, and bioproduction scaling. Headwinds include biotech funding droughts and the complete roll-off of COVID-19 related revenue. * **Pricing dynamics:** High pricing power on proprietary reagents; competitive pricing on basic consumables. * **Revenue recognition notes:** Primarily recognised upon shipment of consumables and reagents. * **Seasonality:** Q4 is typically the strongest quarter due to year-end budget flushes in academic and government institutions. ### Analytical Instruments * **Segment name:** Analytical Instruments * **Revenue driver formula:** Installed Base x Replacement Cycle + New Lab Formations x Equipment Capture Rate * **Historical growth rate:** 3-5% CAGR. * **Key growth levers and headwinds:** Driven by industrial applied markets, materials science, and semiconductor testing. Highly sensitive to macroeconomic capex cycles and interest rates. * **Pricing dynamics:** High-ticket capital purchases (e.g., mass spectrometers) involve negotiated contracts and volume discounts. * **Revenue recognition notes:** Recognised upon installation and customer acceptance of complex instruments. * **Seasonality:** Heavy Q4 weighting as customers exhaust annual capital expenditure budgets. ### Specialty Diagnostics * **Segment name:** Specialty Diagnostics * **Revenue driver formula:** Testing Volumes x Average Price per Test * **Historical growth rate:** 2-4% CAGR (excluding pandemic spikes). * **Key growth levers and headwinds:** Driven by healthcare utilisation rates, aging populations, and transplant volumes. Headwinds include hospital budget constraints and reimbursement rate cuts. * **Pricing dynamics:** Heavily influenced by healthcare reimbursement frameworks (e.g., Medicare/Medicaid in the US). * **Revenue recognition notes:** Recognised upon delivery of diagnostic kits to hospitals and reference labs. * **Seasonality:** Mild seasonality; Q1 and Q4 can see slight upticks due to respiratory virus seasons. ### Laboratory Products and Biopharma Services * **Segment name:** Laboratory Products and Biopharma Services * **Revenue driver formula:** (Clinical Trial Pipeline x Outsourcing Penetration) + (Drug Manufacturing Volumes x CDMO Capture Rate) * **Historical growth rate:** 8-10% CAGR (boosted significantly by the PPD acquisition). * **Key growth levers and headwinds:** Driven by the structural shift towards outsourced clinical trials (CRO) and contract manufacturing (CDMO). Headwinds include clinical trial delays and regulatory scrutiny on manufacturing sites. * **Pricing dynamics:** Long-term contractual pricing with inflation-linked escalators for services; spot pricing for basic lab equipment. * **Revenue recognition notes:** Services revenue is recognised over time based on the percentage of completion of clinical trials or manufacturing batches. * **Seasonality:** Relatively smooth throughout the year due to long-term service contracts. ## Cost Structure ### Variable Costs / COGS * COGS includes raw materials (chemicals, plastics, biological components), direct manufacturing labour, facility overheads, and freight. * Adjusted Gross margin range: 41.0% to 43.5% (2024 adjusted gross margin was 42.2%). * Key input costs include petrochemical derivatives for plastics, specialised biological materials, and global shipping rates. * COGS scales linearly with consumables but exhibits step-function behaviour in the biopharma services segment where manufacturing capacity must be added in large blocks. ### Operating Expenses * **R&D:** Typically runs at 3.0% to 3.5% of revenue (2024 was $1.39 billion or approx. 3.2%). It covers new instrument development and proprietary reagent formulation. * **SG&A:** Adjusted SG&A runs at 15.5% to 16.5% of revenue (2024 was 16.3%). This is heavily headcount-driven, supporting a massive global direct sales force. * **Depreciation & Amortisation:** D&A is exceptionally high due to the amortisation of acquisition-related intangible assets. GAAP operating margins are heavily depressed by this non-cash charge. * **Stock-Based Compensation:** Runs at approximately 0.5% to 1.0% of revenue, which is lower than pure-play tech but material. * **Restructuring / one-time charges:** Frequent, given the company's serial acquisition strategy and subsequent facility consolidations. ### Margin Profile * Adjusted Gross Margin: 41-43% * Adjusted EBITDA Margin: 26-28% * Adjusted Operating Margin: 22-24% (2024 was 22.6%) * GAAP Operating Margin: 16-18% (2024 was 17.1%) * Margins have been relatively stable, supported by the company's Practical Process Improvement (PPI) system which offsets inflation. ## Balance Sheet Structure * Total assets are approximately $95 billion. * Goodwill and intangible assets dominate the balance sheet, representing over 60% of total assets. This is a direct result of historical mega-deals like Life Technologies, Patheon, and PPD. * Working capital profile: * Days Sales Outstanding (DSO): 55-65 days. * Days Inventory Outstanding (DIO): 70-85 days. * Days Payable Outstanding (DPO): 45-55 days. * Net working capital is typically positive and consumes cash as the business grows. * PP&E consists of global manufacturing facilities, CDMO sites, and clinical research laboratories. * Right-of-use assets are material due to the extensive global footprint of leased laboratory and office space. ## Capital Expenditure & Investment * Capex as a percentage of revenue typically ranges from 3.0% to 4.5%. * Maintenance capex accounts for roughly 40% of total capex, while growth capex (60%) is directed towards expanding CDMO capacity and building new bioproduction facilities. * The company is a serial acquirer. M&A is the primary engine for capital deployment, ranging from $1 billion bolt-ons (like Olink) to $15+ billion transformational deals. * Acquisition multiples paid typically range from 15x to 20x forward EBITDA, reflecting the premium nature of life sciences assets. ## Debt & Capital Structure * Total debt is approximately $35 billion, resulting in net debt of roughly $28-30 billion depending on cash balances. * Gross Debt/Adjusted EBITDA ratio typically targets 2.5x to 3.0x, though it spikes immediately following large acquisitions before rapid deleveraging. * Credit rating is investment grade (typically BBB+ / Baa1). * Key debt instruments include senior unsecured notes across USD and EUR tranches, supported by a commercial paper programme. * The company actively repurchases shares to offset dilution and return capital. In 2024, share repurchases totalled $4.0 billion. * The dividend policy is progressive but the yield is low (typically under 0.5%). The 2024 cash dividend payout was approximately $0.58 billion. ## Cash Flow Characteristics * Operating cash flow conversion is excellent, typically exceeding 1.0x of GAAP Net Income due to the massive add-back of acquisition-related amortisation. * Free cash flow margin (FCF / Revenue) typically ranges from 15% to 18%. * The primary bridge from net income to OCF is D&A (specifically intangible amortisation) and deferred income taxes. * Working capital is a moderate use of cash during periods of high organic growth. * The cash tax rate is generally lower than the statutory rate due to global tax planning and R&D tax credits, aligning closely with the adjusted effective tax rate of 10-11%. ## Sheet Structure 1. **Summary:** Dashboard of key metrics, target price, DCF output, and adjusted EPS bridge. 2. **Assumptions:** Hardcoded drivers for macroeconomic inputs, segment growth, margins, and capital allocation. 3. **Revenue_Build:** Detailed build for the four reporting segments plus the intercompany eliminations line. 4. **Income_Statement:** GAAP income statement with a clear reconciliation to Adjusted Operating Income and Adjusted EPS. 5. **Balance_Sheet:** Standard asset, liability, and equity lines, with detailed schedules for Goodwill and Intangibles. 6. **Cash_Flow:** Indirect method starting from GAAP net income, highlighting the D&A add-back. 7. **Debt_Schedule:** Tranche-by-tranche debt maturity profile, interest expense calculation, and commercial paper balances. 8. **Working_Capital:** Schedules for accounts receivable, inventory, and accounts payable driven by DSO, DIO, and DPO. 9. **Depreciation_Amortisation:** Waterfall schedules for PP&E depreciation and acquisition-related intangible amortisation. 10. **DCF:** Unlevered free cash flow calculation, WACC build, and terminal value calculation. ## Key Financial Relationships 1. `Life Sciences Solutions Revenue = Prior Year LSS Revenue * (1 + LSS Organic Growth + LSS M&A Impact + LSS FX Impact)` 2. `Analytical Instruments Revenue = Prior Year AI Revenue * (1 + AI Organic Growth + AI M&A Impact + AI FX Impact)` 3. `Specialty Diagnostics Revenue = Prior Year SD Revenue * (1 + SD Organic Growth + SD M&A Impact + SD FX Impact)` 4. `Lab Products & Biopharma Services Revenue = Prior Year LPBS Revenue * (1 + LPBS Organic Growth + LPBS M&A Impact + LPBS FX Impact)` 5. `Intercompany Eliminations = (LSS Revenue + AI Revenue + SD Revenue + LPBS Revenue) * Historical Elimination Percentage` 6. `Consolidated Revenue = LSS Revenue + AI Revenue + SD Revenue + LPBS Revenue + Intercompany Eliminations` 7. `Adjusted Gross Profit = Consolidated Revenue * Adjusted Gross Margin Assumption` 8. `Adjusted Operating Income = Adjusted Gross Profit - (Consolidated Revenue * Adjusted SG&A Margin) - (Consolidated Revenue * R&D Margin)` 9. `GAAP Operating Income = Adjusted Operating Income - Amortisation of Acquisition-Related Intangibles - Restructuring Costs` 10. `Interest Expense = (Beginning Total Debt + Ending Total Debt) / 2 * Weighted Average Interest Rate` 11. `Adjusted Net Income = (Adjusted Operating Income - Interest Expense + Other Income) * (1 - Adjusted Effective Tax Rate)` 12. `Adjusted EPS = Adjusted Net Income / Diluted Shares Outstanding` 13. `Ending Diluted Shares = Beginning Diluted Shares - (Share Repurchase Amount / Average Share Price) + SBC Dilution` ## Cross-Sheet Dependencies * **Assumptions** feeds all operational drivers in the **Revenue_Build**, **Income_Statement**, and **Working_Capital** sheets. * **Revenue_Build** feeds the top line of the **Income_Statement** and drives the activity levels in the **Working_Capital** sheet. * **Working_Capital** outputs the change in NWC, which feeds directly into the **Cash_Flow** sheet. * **Depreciation_Amortisation** feeds the operating expenses in the **Income_Statement** (for GAAP metrics) and the non-cash add-backs in the **Cash_Flow** sheet. * **Debt_Schedule** calculates interest expense for the **Income_Statement** and tracks principal repayments for the **Cash_Flow** sheet. * **Cash_Flow** generates the ending cash balance, which feeds the **Balance_Sheet** to ensure it balances. ## Sign Convention * Revenues and asset balances are positive. * Expenses (COGS, SG&A, R&D, Interest) are represented as positive numbers in their specific schedules but subtracted in aggregation formulas (e.g., Gross Profit = Revenue - COGS). * Intercompany Eliminations must be entered as a negative number in the revenue build. * Cash outflows (capex, share repurchases, dividends, debt repayments) are negative on the Cash Flow statement. * Cash inflows (debt issuance, operating cash flow) are positive on the Cash Flow statement. ## Things Most Likely to Go Wrong * **Intercompany Eliminations:** Thermo Fisher has significant cross-selling between segments. The model must include a negative eliminations line (historically around 4.0% to 4.5% of gross segment revenue) or consolidated revenue will overstate reality. * **GAAP vs Adjusted Metrics:** The gap between GAAP and Adjusted EPS is massive (e.g., $16.53 GAAP vs $21.86 Adjusted in 2024). The model must explicitly forecast acquisition-related amortisation to bridge these two figures accurately. * **COVID-19 Base Effects:** Historical growth rates from 2020-2022 are heavily distorted by pandemic testing revenue. Do not use 5-year historical averages for segment growth; use management's normalised long-term targets or post-2023 baselines. * **FX Translation:** As a global business, currency swings can impact revenue by 2-4% annually. The model should separate organic growth from FX impacts in the revenue build. * **Share Count Dynamics:** The company aggressively buys back stock, but also issues equity for employee compensation. The net share reduction must be modelled carefully to calculate EPS correctly. * **Tax Rate Discrepancies:** The GAAP tax rate and the Adjusted tax rate differ significantly due to the tax treatment of intangible amortisation. Ensure the Adjusted Net Income calculation uses the Adjusted tax rate (approx. 10-11%). * **Capital Allocation Circularity:** If the model assumes excess cash is automatically swept into share repurchases, it can create a circular reference with the share price, EPS, and equity value. Use a manual toggle for share repurchases. * **Goodwill Accumulation:** If forecasting future M&A, ensure the balance sheet reflects the addition of Goodwill and Intangibles, and the cash flow statement reflects the cash outflow for acquisitions. ## Validation Checks * "Intercompany Eliminations should be between -4.0% and -4.5% of total gross segment revenue." * "Adjusted Gross Margin should remain in the 41.0% to 43.0% range based on recent historical performance." * "Adjusted Operating Margin should be between 22.0% and 24.0%; flag if it expands beyond this without a clear mix-shift rationale." * "Capex as a percentage of revenue should run between 3.0% and 4.5%." * "Adjusted Effective Tax Rate should be approximately 10.0% to 11.5%." * "Free Cash Flow conversion (FCF / Adjusted Net Income) should be near or above 85-90%." * "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every forecasted period." * "Gross Debt to Adjusted EBITDA should not exceed 3.5x unless a major acquisition is explicitly modelled in that year." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | LSS Organic Growth | 2.0 | % | Normalised growth post-COVID testing roll-off | | AI Organic Growth | 4.0 | % | Steady replacement cycle and industrial demand | | SD Organic Growth | 3.0 | % | Stable clinical testing volumes | | LPBS Organic Growth | 5.0 | % | Continued outsourcing trends in clinical trials and CDMO | | Intercompany Eliminations | -4.2 | % | Historical average of gross segment revenues | | Adjusted Gross Margin | 42.2 | % | Actual 2024 adjusted gross margin | | Adjusted SG&A Margin | 16.3 | % | Actual 2024 adjusted SG&A margin | | R&D Margin | 3.2 | % | Actual 2024 R&D spend as % of revenue | | Adjusted Effective Tax Rate | 10.5 | % | Management guidance and recent historical average | | Capex % of Revenue | 3.5 | % | Historical average required to support bioproduction network | | DSO | 60 | Days | Based on 2023/2024 average receivables turnover | | DIO | 75 | Days | Based on 2023/2024 average inventory turnover | | DPO | 50 | Days | Based on 2023/2024 average payables turnover | | Annual Share Repurchases | 4000 | USD Millions | Matches 2024 actual capital return behaviour | | Annual Dividend Growth | 10.0 | % | Historical progressive dividend policy | | Weighted Average Interest Rate | 3.8 | % | Blended rate of existing senior notes and commercial paper | | WACC | 7.5 | % | Standard discount rate for large-cap life sciences tools | | Terminal Growth Rate | 2.5 | % | Aligns with long-term global GDP and healthcare spending growth | ## Data Sources & Benchmarks * **Filings:** SEC EDGAR for Thermo Fisher Scientific (TMO) 10-K, 10-Q, and 8-K filings. The Investor Relations page provides the crucial "Reconciliation and Financial Package" which bridges GAAP to Adjusted metrics. * **Peers for Benchmarking:** Danaher (DHR), Agilent Technologies (A), Waters Corporation (WAT), and IQVIA Holdings (IQV). * **Industry Data:** IQVIA Institute for Human Data Science (for clinical trial start data and biopharma R&D spend trends). * **Consensus Estimates:** FactSet or Bloomberg for forward-looking street estimates on segment growth and adjusted EPS. ## Sources * Thermo Fisher Scientific Q4 and Full Year 2024 Earnings Release (January 30, 2025) * Thermo Fisher Scientific 2024 Form 10-K * Thermo Fisher Scientific Investor Relations Financial Reconciliations (www.thermofisher.com) --- ## Frequently asked questions ### What does Thermo Fisher Scientific do? Thermo Fisher Scientific is the world's largest supplier of scientific instrumentation, reagents, consumables, and software to life sciences, clinical, and industrial laboratories. The company also provides extensive outsourced clinical trial and contract manufacturing services to the pharmaceutical industry. ### What are the primary revenue drivers for Thermo Fisher Scientific? Thermo Fisher Scientific's main revenue drivers stem from its Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics segments. Their business model combines recurring consumables and services with capital equipment sales, offering a hybrid revenue stream. ### What is Thermo Fisher Scientific's typical capital expenditure as a percentage of revenue? Thermo Fisher Scientific's capital expenditure as a percentage of revenue typically ranges from 3.0% to 4.5%. Growth capex, which accounts for approximately 60% of total capex, is primarily directed towards expanding CDMO capacity and building new bioproduction facilities. ### What is the assumed revenue growth rate for Thermo Fisher Scientific in the financial model? The financial model for Thermo Fisher Scientific incorporates a revenue growth assumption of approximately 13.8%. This key input helps forecast the company's future financial performance and supports the comprehensive equity valuation. ### How does M&A activity influence Thermo Fisher Scientific's capital deployment and valuation? M&A is the primary engine for Thermo Fisher Scientific's capital deployment, encompassing both smaller bolt-on acquisitions and larger transformational deals. Acquisition multiples paid typically range from 15x to 20x forward EBITDA, reflecting the premium nature of assets in the life sciences sector. ### Can I download an Excel financial model for Thermo Fisher Scientific? Yes, an Excel financial model for Thermo Fisher Scientific is available for download. This model offers a comprehensive equity valuation and capital allocation forecast, allowing analysts to determine the company's intrinsic value and assess its capacity for future M&A. [Interactive forecast calculator](https://finamodel.com/companies/thermo-fisher-scientific/forecast)